Article

DMEK outcomes favorable after mid-term duration of follow-up

Findings from a mid-term evaluation of the first Descemet Membrane Endothelial Keratoplasty (DMEK) cohort show that the procedure results in a near complete visual recovery that is achieved at 6 months and seems to remain stable for at least up to 6 years, said Fook Chang Lam, MD.

Chicago-Findings from a mid-term evaluation of the first Descemet Membrane Endothelial Keratoplasty (DMEK) cohort show that the procedure results in a near complete visual recovery that is achieved at 6 months and seems to remain stable for at least up to 6 years, said Fook Chang Lam, MD.

The world’s first DMEK was performed by Gerrit Melles, MD, PhD, and colleagues at the Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands, more than 6 years ago.

Now, data from the first 300 operated eyes followed for at least 2 years prove that the procedure continues to be effective in the mid-term, Dr. Lam said.

“Excluding eyes with low visual potential, best-corrected visual acuity was 20/40 or better in more than 95% of eyes by 6 months,” he said. “And, what is really remarkable, the number of patients achieving 20/20 and 20/17 continues to increase with the passage of time.”

He also reported safety outcomes. Endothelial cell density decreased 34% in the first 6 months after surgery. Thereafter, it declined at a steady annual rate of 8%.

 

The review of postoperative complications showed such events were very rare after the first 6 months of surgery, but also demonstrated the effect of the learning curve. Although the overall graft survival rate was 86%, Dr. Lam pointed out that the success rate was much higher when considering only the last 100 to 200 cases.

“Early primary graft failure occurred in four eyes, for a rate of 1.3% rate,” he said. “However, excluding three cases that occurred in our learning curve, the rate decreases to 0.04%.”

The rate of secondary glaucoma was 1.3%, and iatrogenic cataract occurred in 9.2% of phakic eyes. There was a 0.7% rate of late-onset graft failure, and graft rejection occurred at a rate of 2% from 2 to 6 years, although two-thirds of those patients regained corneal clarity with topical treatment.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.